| Entry |
|
|---|
| Name |
Tripelennamine hydrochloride (USP);
PBZ-SR (TN) |
|---|
| Formula |
C16H21N3. HCl
|
|---|
| Exact mass |
291.1502
|
|---|
| Mol weight |
291.819
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Anti-allergic agent
DG01557 Histamine receptor antagonist
DG01482 Histamine receptor H1 antagonist
Metabolizing enzyme inhibitor
DG01645 CYP2D6 inhibitor
|
|---|
| Remark |
|
|---|
| Efficacy |
Antiallergic, H1 receptor antagonist |
|---|
| Comment |
Phenbenzamine derivative
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
|
|---|
| Interaction |
CYP inhibition: CYP2D6 [HSA: 1565]
|
|---|
| Structure map |
| map07212 | Histamine H1 receptor antagonists |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
D DERMATOLOGICALS
D04 ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
D04A ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
D04AA Antihistamines for topical use
D04AA04 Tripelennamine
D02091 Tripelennamine hydrochloride (USP)
R RESPIRATORY SYSTEM
R06 ANTIHISTAMINES FOR SYSTEMIC USE
R06A ANTIHISTAMINES FOR SYSTEMIC USE
R06AC Substituted ethylene diamines
R06AC04 Tripelennamine
D02091 Tripelennamine hydrochloride (USP)
Risk category of Japanese OTC drugs [BR:br08312]
Second-class OTC drugs
Inorganic and organic chemicals
Tripelennamine
D02091 Tripelennamine hydrochloride (USP)
Drug groups [BR:br08330]
Anti-allergic agent
DG01557 Histamine receptor antagonist
DG01482 Histamine receptor H1 antagonist
DG00383 Tripelennamine
D02091 Tripelennamine hydrochloride
Metabolizing enzyme inhibitor
DG01645 CYP2D6 inhibitor
DG00383 Tripelennamine
D02091 Tripelennamine hydrochloride
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Histamine
HRH1
D02091 Tripelennamine hydrochloride (USP)
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D02091
Drug groups [BR:br08330]
Anti-allergic agent
DG01557 Histamine receptor antagonist
DG01482 Histamine receptor H1 antagonist
DG00383 Tripelennamine
Metabolizing enzyme inhibitor
DG01645 CYP2D6 inhibitor
DG00383 Tripelennamine
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 20
1 C8x C 20.1082 -16.9077
2 C8x C 20.1082 -18.3122
3 C8x C 21.3245 -19.0145
4 C8x C 22.5409 -18.3122
5 C8y C 22.5409 -16.9077
6 C8x C 21.3245 -16.2055
7 N5x N 23.7572 -19.0145
8 C8y C 24.9735 -18.3122
9 N1c N 24.9735 -16.9077
10 C1b C 23.7572 -16.2055
11 C8x C 23.7572 -20.4190
12 C8x C 24.9735 -21.1212
13 C8x C 26.1899 -20.4190
14 C8x C 26.1899 -19.0145
15 C1b C 26.1749 -16.2140
16 C1b C 27.3670 -16.9022
17 N1c N 28.5616 -16.2124
18 C1a C 29.7551 -16.9014
19 C1a C 28.5616 -14.8012
20 X Cl 30.0300 -19.6700
BOND 20
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 7 8 1
8 8 9 1
9 9 10 1
10 5 10 1
11 7 11 2
12 11 12 1
13 12 13 2
14 13 14 1
15 8 14 2
16 9 15 1
17 15 16 1
18 16 17 1
19 17 18 1
20 17 19 1
|
|---|
